Schall, Brown & Schwartz LLP is reminding investors about a securities class action against Replimune Group, Inc. over alleged violations of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5. The proposed class covers investors who purchased Replimune shares under the ticker REPL between Oct. 20, 2025, and April 10, 2026. The deadline to contact the firm is Oct. 5, 2026. The complaint alleges that Replimune made false and misleading statements by failing to address study-design concerns previously communicated by the FDA (U.S. drug regulator) about its Biologics License Application, or BLA (application for biologic-drug approval). It further alleges that the company submitted an unplanned analysis of its RP1-104 study using only 10% of planned enrollment, making FDA rejection of the BLA likely. The firm says investors suffered losses when the market learned the alleged truth. The class has not been certified, and investors are not represented by an attorney unless certification occurs or they otherwise join the case. Appointment as lead plaintiff is not required to participate in any recovery.